4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

F. Cardoso, E. Senkus, A. Costa, E. Papadopoulos, M. Aapro, F. André, N. Harbeck, B. Aguilar Lopez, C. H. Barrios, J. Bergh, L. Biganzoli, C. B. Boers-Doets, M. J. Cardoso, L. A. Carey, J. Cortés, G. Curigliano, V. Dié Ras, N. S. El Saghir, A. Eniu, L. FallowfieldP. A. Francis, K. Gelmon, S. R.D. Johnston, B. Kaufman, S. Koppikar, I. E. Krop, M. Mayer, G. Nakigudde, B. V. Offersen, S. Ohno, O. Pagani, S. Paluch-Shimon, F. Penault-Llorca, A. Prat, H. S. Rugo, G. W. Sledge, D. Spence, C. Thomssen, D. A. Vorobiof, B. Xu, L. Norton, E. P. Winer

Research output: Contribution to journalArticle

334 Citations (Scopus)

Abstract

Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].

Original languageEnglish
Pages (from-to)1634-1657
Number of pages24
JournalAnnals Of Oncology
Volume29
Issue number8
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • ABC
  • Advanced
  • Breast cancer
  • ESO-ESMO
  • Guidelines
  • Metastatic

Fingerprint Dive into the research topics of '4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)'. Together they form a unique fingerprint.

Cite this